Evaluating BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as an equity purchase involves examining its commercial biotechnology pipeline, rare genetic disease therapies, and revenue growth. What is your specific investment horizon, risk profile, and target portfolio asset allocation? Consulting a licensed financial advisor is recommended before executing any trades in pharmaceutical equities.